Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Present at the Oppenheimer & Co., Inc. 25th Annual Healthcare Conference

NEW YORK, Dec. 2, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Dr. Irach Taraporewala, Chief Executive...
October 27, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Host Key Opinion Leader Meeting and Webcast on October 31 in New York City

NEW YORK, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will host a Key Opinion Leader analyst...
October 20, 2014 07:15 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces New Positive Anatomic and Visual Acuity Data on OHR-102 (Squalamine Eye Drops) IMPACT Study Presented at the 2014 American Academy of Ophthalmology Scientific Meeting

Reduction of Subretinal Hyperreflective Material (SHRM) Induced by OHR-102 Correlates With Improved Vision Outcomes Regression of the SHRM Biomarker in Wet-AMD and Vision Improvement is Consistent...
October 14, 2014 07:15 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Successful End of Phase II Meeting With the FDA on Squalamine Eye Drops (OHR-102) in Wet AMD

Primary Endpoint for Approval to be Based on Visual Acuity Improvements at 9 Months Phase III Trials to Commence in the First Half of 2015 NEW YORK, Oct. 14, 2014 (GLOBE NEWSWIRE) -- Ohr...
October 07, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the 2014 American Academy of Ophthalmology Scientific Meeting

NEW YORK, Oct. 7, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that additional positive anatomic and visual...
September 09, 2014 09:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Clinical Data Presentations at the Retina Society 47th Annual Scientific Meeting

NEW YORK, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, announced today that data from the IMPACT study, a phase II...
August 13, 2014 08:30 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Additional Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Wet-AMD; The IMPACT Study

NEW YORK, Aug. 13, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced additional interim data from the Phase II study...
August 11, 2014 09:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Squalamine Eye Drop (OHR-102) Phase II Clinical Data in Retinal Vein Occlusion

NEW YORK, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced data supporting the use of Squalamine Eye Drops...
August 08, 2014 08:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical to Present at the 2014 Wedbush Life Sciences Management Access Conference

NEW YORK, Aug. 8, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that Sam Backenroth, Chief Financial Officer, will...
August 07, 2014 09:00 ET | Source: Ohr Pharmaceutical, Inc.

Ohr Pharmaceutical Announces Upcoming Squalamine Eye Drop Clinical Data Presentations at the 2014 Annual Meeting of the American Society of Retina Specialists

NEW YORK, Aug. 7, 2014 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that data from clinical studies evaluating...